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Dr David H. Adams (New York, NY). Rakesh, I really enjoyed
this presentation and your leadership in the field. So much of the
evidence base that serves as a foundation for the American
College of Cardiology/American Heart Association (ACC/AHA)
guidelines have originated from the Mayo experience, and your
new data are provocative and will have implications for future
guidelines. Let us explore a few details.
My first question is, what led you to focus on patients with an
EF> 60% instead of all-comers, given that the surgical trigger
point around 60% has been an established criterion in the
ACC/AHA guidelines for the past several years based on historical
data from the Mayo? I imagine there was some curiosity among
your colleagues about this study in the first place, because these
results could well redefine what we have held true for the past
few decades.
Dr Suri. Thank you, Dr Adams, and we would like to
acknowledge your international leadership and contributions to
this field.
You make an important point, and that is, why should we
consider operating in advance of established guidelines?
Comparative effectiveness research recently published,
including the Mitral Regurgitation International DAtabase
(MIDA) analysis late last year and the study by Kang and
colleagues several weeks ago, both point us in the direction of
understanding to a greater degree the ability of early mitral valve
repair—which is low risk and associated with low morbidity in the
modern era—to improve late outcomes. This is true, in terms of
both enhanced late survival and freedom from heart failure
many years after early mitral valve repair. A growing population
of patients thus present to us at Mayo Clinic without the
typical class I or IIA triggers for operation and elect to undergo
early correction of severe degenerative MR, cognizant of
these benefits. Most, if not all, of these patients, have a ‘‘normal’’
preoperative EF.
But what struck us in this particular population of patients was
that, despite having what was thought to be ‘‘normal’’ ventricular
function before surgery, a proportion of these patients develop
profound LV dysfunction immediately after separation from
cardiopulmonary bypass. Typically, these individuals require
inotropic support for a couple of days and leave the hospital
with an EF of<50%. The first question that many have asked is,
‘‘What happened during the operation?’’
Well, we went back to our operative notes and found no
important technical differences in the course of the operation.
These are often patients who have 20- or 30-minute crossclamp
times and successful mitral valve repair operations with none-to-
trivial residual MR, yet they developed LV dysfunction. This led
us to ask ‘‘why’’ and ‘‘when’’ and to further investigate thisgery c December 2014
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Dr Adams. It is a point Carpentier made, and it is so relevant to
all of us. Often, our patient experience triggers our trying to answer
a question.
My next point is about the current guidelines for the
end-systolic diameter of 40 mm and the estimated pulmonary
artery pressure of 55 mm Hg as the cutoff for decision-making
for surgical intervention. Why did you choose the trigger levels
you highlighted today? How did you settle on the end-systolic
diameter of 36 mm, for example, as a potential trigger instead of
another number?
Dr Suri. Thank you. That is a very good question. As those in the
room know who have worked to identify cutpoints, it is a very sta-
tistically ‘‘intensive’’ process. I can summarize by saying we
worked closely with our statisticians to construct multiple logistic
regression analyses and identified threshold values of LVESD
and RVSP that predicted the development of postoperative LVEF
<40% with the greatest discriminatory power. We assessed this us-
ing the areas under the receiver operating characteristic curves.
The next point to emphasize is that these are not magical
numbers or cutpoints. We do not imagine they will necessarily be
embedded into future iterations of the recommendations guiding
treatment of all patients with degenerative MR. However, we can
state that these thresholds appear influential in predicting postoper-
ative LV dysfunction specifically in the present population we stud-
ied with an EF>60% on the preoperative echocardiogram. These
results will hopefully prompt initiation of the next generation of
clinical trials to further study advanced indications for the perfor-
mance of mitral valve repair, specifically in patients with echocar-
diographically documented severe MR by proximal isovelocity
surface area measurements.
Dr Adams. Let us continue on that theme and talk about
additive value now. Can you tell us whether you examined the
outcomes of patients who had the combination of an elevated
end-systolic diameter of 36 mm and pulmonary pressure of 45
mm Hg? A few years ago, Triboully and colleagues emphasized
the additive value of near trigger points, not exceeding one
but just near trigger points, and I wonder if you have done this
exploratory analysis?
Dr Suri. That is a very good question, and I would say the
results of the present study have piqued our interest in pursuing
additional subset analyses. Just ‘‘back-of-napkin’’ calculations,
we have combined those 2 trigger points—LVESD > 36 mm
and RVSP> 49 mm Hg—and arrived at an odds ratio that was
greater in conjunction than for each of them separately. We
estimated an approximately eightfold greater risk of developing
postoperative LVEF< 40% when both of those trigger points
were observed prior to mitral valve repair.
Dr Adams. This is really important, because we need to move
away from single-number triggers and start thinking about the com-
bination and your trigger points, and I expect when you do that anal-
ysis, we might be even lower than 36 or 45 in combination.
My next point is about your bypass times, which you mentioned
were extremely short. I find that actually very sobering, in
particular, as the guidelines are moving us toward asymptomatic
intervention in class IIA indications. Do you have any thoughts
about that in terms of why this is happening or what we need to
learn for the future?The Journal of Thoracic and CarDr Suri. That is a great question. As I mentioned previously,
once a patient with asymptomatic MR leaves the operating room
with no MR but with an EF that is 40%, the first question that
people ask the surgeon is, ‘‘What happened, how long was the
crossclamp time?’’ Well, what struck us was that the crossclamp
and bypass times were not different between those with and
without postoperative LV dysfunction. In other words, the
predisposition for LV dysfunction was set before the performance
of mitral valve repair, and that is something we all need to
recognize and investigate further.
Dr Adams.My last comment is about the clinical implications
of your results for our daily practice. Your thoughts about strain,
other analyses of the ventricle outside of the ejection fraction?
Finally, how are you currently treating patients with a lower EF
after mitral valve repair for degenerative disease?
Thank you again for this provocative analysis.
Dr Suri. Thank you, Dr Adams. To be very quick with the
response for the sake of time, the next wave of prognostic
markers that will be investigated to help advance our understanding
of the pathophysiologic consequences of severe chronic degenera-
tive MR will include assessment of brain natriuretic peptide, exer-
cise testing, LV strain, and left atrial chamber size. We, and others
around theworld, are currently investigating the sensitivity and spec-
ificity of these modalities in attempting to elucidate the ideal timing
of mitral valve repair in asymptomatic patients in advance of the
onset of guideline-based triggers.
What do we do when we document LV dysfunction on the
predismissal echocardiogram? Dr Schaff, myself, and my
colleagues at Mayo Clinic, when we are faced with a patient
who has an EF< 50% after mitral valve repair, we generally
institute angiotensin converting enzyme inhibitor therapy at
dismissal. We also consider those patients candidates for
increased intensity of medical and echocardiographic surveillance
when they return to their home community.
Upon discovery of profound postoperative dysfunction, an EF
of<40%, after mitral valve repair in a patient with a previously
normal EF, we consider involving our heart failure colleagues
before dismissal from the hospital, because we believe these
patients should be monitored with even greater frequency.
Dr Niv Ad (Falls Church, Va). Rakesh, I enjoyed your
presentation. I think, on the same line, it is important to understand
what your definition of a successful repair is, because we all know
that leaving the operating room without MR is not always enough.
Also, what happened to the patient who died earlier or had a
greater mortality rate with regard to their mitral repair status?
Was the successful repair stable throughout the study or did you
have grade 2 MR in this group that died?
Dr Suri. There was 0.2% mortality in this population, so 4
deaths in the whole study. It was very low.
To the point about what constitutes a successful repair, at Mayo
Clinic, we rely on our echocardiographic assessment, separating
from cardiopulmonary bypass with trivial-to-mild or less MR,
and a gradient that is<3, typically. Is that what you mean?
Dr Ad. We all know that leaving the operating without MR is
not necessarily enough, and it is not definitely reflective of the
long-term success of the mitral valve repair.
Dr Suri. So echocardiographic predictors?
Dr Ad. Yes.diovascular Surgery c Volume 148, Number 6 2761
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the echocardiogram, such as coaptation depth, and confirm smooth
nonturbulent outflow, the absence of systolic anterior motion, and
the absence of regional wall motion abnormalities.
Those are the typical things. Is that what you are getting at?
Dr del Nido. We are going to have to keep going with this
discussion. Perhaps they can continue afterward. One more very
short question, please.
Dr Mohamed Emara (Cairo, Egypt). I congratulate you for
this nice presentation. Did you try the end-systolic phase indexes
rather than the ejection phase indexes? As we all know, in chronic
volume overload, when a leak is present in the mitral valve, EF is
usually higher than normal, so one might start with the wrong
judge on the ventricle.
Dr Suri. Sorry, did we consider other modalities?2762 The Journal of Thoracic and Cardiovascular SurDr Emara. No, other indexes to evaluate the left ventricle. You
used the ejection phase indexes.
Dr Suri. It is a very good point. We have to remember 1
critical thing, and when we were writing the report we spoke
about this several times. That is, although we might all use a
varied and heterogeneous array of modalities to assess LV
function in research studies, the reality is that echocardio-
graphic assessment of LV systolic function using EF is ubiq-
uitous in current clinical practice and deeply embedded in
current clinical practice guidelines. Thus, although we can
endeavor to explore different experimental means of assessing
contractility and latent dysfunction, the truth is we did not
examine in the present study in order to permit our findings
to be generalized in the broader international clinical
community.gery c December 2014
